JACQUELINE KIRK: Open Payments
NPI 1326719964 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,524 in 65 payments from 11 companies in 2025. Trend: 2023 $2,073 · 2024 $1,622 · 2025 $1,524
Food & beverage: $1,524
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 15 | $441 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $317 |
| ABBVIE INC. | 14 | $161 |
| Alkermes, Inc. | 6 | $135 |
| Alpha Cognition USA, Inc. | 4 | $120 |
| Teva Pharmaceuticals USA, Inc. | 1 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $69 |
| Axsome Therapeutics, Inc. | 3 | $59 |
| Vanda Pharmaceuticals Inc. | 2 | $53 |
| Otsuka America Pharmaceutical, Inc. | 1 | $31 |
Products named: INGREZZA, CAPLYTA, VRAYLAR, ARISTADA, Zunveyl, AUSTEDO XR, TRINTELLIX, Auvelity.
Industry payments across MO — which companies pay providers there.
